2nd hall

Selected poster presentations					
PC001	Day 3	7:30-8:30	Regional Variation of Amyloid Deposition in an Autopsy Heart of a Senile Systemic Amyloidosis Case with Long-Term Clinical Course	Korai, Kengo	Suita, Japan
PC002	Day 3	7:30-8:30	The role of genetic factors of Alzheimer and Parkinson disease as modulators of age-at-onset on Familial Amyloid Polyneuropathy	Lemos, Carolina	Porto, Portugal
PC060	Day 3	7:30-8:30	The First Case of Wild-Type Cystatin C Amyloidosis Identified from Granulomatous Amyloidoma in the Rectum	Yoshinaga, Tsuneaki	Matsumoto, Japan
PC065	Day 3	7:30-8:30	Relation Between Myocardial Amyloid Burden by 18F-florbetapir PET and Severity of Heart Failure in Light Chain Amyloidosis	El-Sady, Mohamed Samir	Boston, United States
PC066	Day 3	7:30-8:30	Treatment with pomalidomide and dexamethasone in patients with light chain AL amyloidosis and multiple myeloma	Basset, Marco	Pavia, Italy
PC067	Day 3	7:30-8:30	Systemic heavy and light chain amyloidosis presenting nephrotic syndrome and congestive heart failure: A case presentation and literature review	Otaka, Yukihiro	Takasaki, Japan

3rd floor

PC001	Day 3	13:00-14:00	Regional Variation of Amyloid Deposition in an Autopsy Heart of a Senile Systemic Amyloidosis Case with Long-Term Clinical Course	Korai, Kengo	Suita, Japan
PC002	Day 3	13:00-14:00	The role of genetic factors of Alzheimer and Parkinson disease as modulators of age-at-onset on Familial Amyloid Polyneuropathy	Lemos, Carolina	Porto, Portugal
PC003	Day 3	13:00-14:00	Symptomatic Transthyretin Amyloidosis in a Young Afro-Caribbean Female with a Thr60Ala mutation	Maurer, Mathew	New York, United States
PC004	Day 3	13:00-14:00	Defining the minimum criteria for diagnosis of active disease in the follow-up of an identified carrier of a TTR gene mutation	Conceicao, Isabel	Lisbon, Portugal
PC005	Day 3	13:00-14:00	Disease evolution of ATTR amyloidosis observed on a bone-scan	Hazenberg, Bouke	Groningen, Netherlands
PC006	Day 3	13:00-14:00	Contradictory findings between NaF-PET and diphosphonate bone scintigraphy in a patient with ATTR amyloidosis and cardiac involvement	Hazenberg, Bouke	Groningen, Netherlands
PC007	Day 3	13:00-14:00	Cardiomyocytes separated by expanded extracellular matrix containing hyaluronan in ATTR patients	Hellman, Urban	Umeå, Sweden
PC008	Day 3	13:00-14:00	Long term outcome after liver transplantation in Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP)	Plante-Bordeneuve, Violaine	Créteil, France
PC009	Day 3	13:00-14:00	In vivo target engagement and phagocytosis of aggregated TTR by a conformation-specific TTR antibody	Higaki, Jeffrey N.	South San Francisco, United States

PC010	Day 3	13:00-14:00	Smart Somatotopic Quantitative Sensory Testing findings in Hereditary Transthyretin Amyloidosis with Polyneuropathy	Pinto, Marcus Vinicius R	Rochester, United States
PC011	Day 3	13:00-14:00	Tafamidis versus Liver Transplantation as First-Line Therapy for Hereditary Transthyretin Amyloidosis	Algalarrondo, Vincent	Clamart, France
PC012	Day 3	13:00-14:00	Design and Evaluation of shRNA Complex with Cyclodextrin/Dendrimer Conjugate for Treatment of Transthyretin Amyloidosis	Inoue, Masamichi	Kumamoto, Japan
PC013	Day 3	13:00-14:00	A single-center experience in 25 consecutive second recipieients after domino liver transplantation	Narita, Yasuko	Kumamoto, Japan
PC014	Day 3	13:00-14:00	Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis	Ruiz-Negron, Natalia	Salt Lake City, United States
PC015	Day 3	13:00-14:00	Generation and characterization of a novel antibody for the treatment of transthyretin amyloidosis	Higuchi, Hirofumi	Kikuchi, Japan
PC016	Day 3	13:00-14:00	Taste disturbance in hereditary transthyretin amyloidosis	Hayashi, Koji	Kanazawa, Japan
PC017	Day 3	13:00-14:00	Characteristics of Korean patients with hereditary transthyretin amyloidosis	Choi, Kyomin	Seoul, Korea
PC018	Day 3	13:00-14:00	Minor salivary gland biopsy for the diagnosis of wild-type transthyretin amyloidosis	Buob, David	Paris, France
PC019	Day 3	13:00-14:00	“Nonbiopsy diagnosis” of wild type transthyretin cardiac amyloidosis: What to do with coincident monoclonal gammopathy?	Kwok, Fiona	Sydney, Australia
PC020	Day 3	13:00-14:00	Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect	Lee, Chi-Chang	Taipei, Taiwan
PC021	Day 3	13:00-14:00	Lead Optimization of Resilient Second-Generation Transthyretin Stabilizers for Multiple Target-Product Profiles: Where Do We Go From Here?	Brito, Rui_M.	Coimbra, Portugal
PC022	Day 3	13:00-14:00	Age-dependent cognitive dysfunction in untreated ATTRV30M patients	Cavaco, Sara	Porto, Portugal
PC023	Day 3	13:00-14:00	Electrocardiographic features of hereditary V30M transthyretin amyloidosis, different phenotypes with similar findings	Pilebro, Björn	Umeå, Sweden
PC024	Day 3	13:00-14:00	A specific and versatile immunoassay suitable for the diagnosis of transthyretin amyloidosis (ATTR) using a wide range of biological samples	Buxbaum, Joel N	LaJolla, United States
PC025	Day 3	13:00-14:00	Clinical manifestations in hereditary amyloidosis with the variant Glu54Gln transthyretin	Coriu, Daniel	Bucharest, Romania
PC026	Day 3	13:00-14:00	Progression to cardiac disease in the first four years after diagnosis in ATTRm amyloidosis: The Groningen Amyloid Cohort (GAC)	Hazenberg, Bouke P	Groningen, Netherlands
PC027	Day 3	13:00-14:00	Kidney involvement differs between patients with type A and type B fibrils in Swedish ATTR V30M amyloidosis	Westermark, Per	Uppsala, Sweden
PC028	Day 3	13:00-14:00	Clinical characteristics and outcome of patients with wild-type transthyretin and AL cardiac amyloidosis confirmed by mass spectrometry	Parkin, Stephen	Vancouver, Canada

PC029	Day 3	13:00-14:00	Domino liver transplantation and acquired familial amyloid polyneuropathy	Coelho, Teresa	Porto, Portugal
PC030	Day 3	13:00-14:00	Case report of a young patient with transthyretin amyloidosis associated with Gly67Ala mutation	Salihoglu, Ayse	Istanbul, Turkey
PC031	Day 3	13:00-14:00	Gastrointestinal symptoms in liver transplanted transthyretin amyloidosis patients compared to transplanted and non-transplanted controls	Wixner, Jonas	Umeå, Sweden
PC032	Day 3	13:00-14:00	The diagnostic utility of neurophysiologic tests for early diagnostic of Transthyretin Familial Amyloid Polyneuropathy	Sousa, Ana_Paula	Porto, Portugal
PC033	Day 3	13:00-14:00	The Novel A19D mutation inhibits Transthyretin tetramerization	Ferreira, Priscila	Rio De Janeiro, Brazil
PC034	Day 3	13:00-14:00	Impact of hereditary transthyretin-mediated amyloidosis on use of health care services: An analysis of the APOLLO Study	Schmidt, Hartmut	Cambrdige, United States
PC035	Day 3	13:00-14:00	Impact of hereditary transthyretin-mediated amyloidosis on daily living and work productivity: Baseline results from APOLLO	Berk, John	Cambrdige, United States
PC036	Day 3	13:00-14:00	Relationship between transthyretin knockdown and change in mNIS+7: Findings from the patisiran phase 2 open-label extension and phase 3 APOLLO studies for patients with hereditary transthyretin-mediated amyloidosis	Polydefkis, Michael	Cambrdige, United States
PC037	Day 3	13:00-14:00	Changes in neuropathy stage in patients with hereditary transthyretin-mediated amyloidosis following treatment with patisiran, an investigational RNAi therapeutic: An analysis from the phase 3 APOLLO study	Gonzalez-Duarte, Alejandra	Cambrdige, United States
PC038	Day 3	13:00-14:00	Home infusion administration of patisiran, an investigational RNAi therapeutic in patients with hereditary transthyretin-mediated amyloidosis: An analysis of safety and adherence	Gillmore, Julian	Cambrdige, United States
PC039	Day 3	13:00-14:00	Long-term use of patisiran, an investigational RNAi therapeutic, in patients with hereditary transthyretin-mediated amyloidosis: Baseline demographics and preliminary data from global open label extension study	Suhr, Ole	Cambrdige, United States
PC040	Day 3	13:00-14:00	Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated amyloidosis: Regional and genotypic subgroup analyses from the APOLLO study	Coelho, Teresa	Cambrdige, United States
PC041	Day 3	13:00-14:00	Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis	Taubel, Jorg	Cambrdige, United States
PC042	Day 3	13:00-14:00	Wild-type transthyretin amyloidosis is associated with sensorineural hearing loss in elderly : The Amylo-DEAFNESS pilot study	Kharoubi, Mounira	Créteil, France
PC043	Day 3	13:00-14:00	Clinical Sequencing of the Transthyretin Gene at the Mayo Clinic: Review of the First 5,000 Cases.	Highsmith, W. Edward	Rochester, United States
PC044	Day 3	13:00-14:00	APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthretin-mediated amyloidosis: 18-month safety and efficacy in subgroup of patients with cardiac involvement	Kristen, Arnt	Cambrdige, United States
PC045	Day 3	13:00-14:00	Diflunisal tolerability in cardiac amyloidosis: a single center experience	Donnelly, Joseph P	Shaker Heights, United States

PC046	Day 3	13:00-14:00	Carpal tunnel syndrome and amyloid cardiomyopathy	Donnelly, Joseph P	Shaker Heights, United States
PC047	Day 3	13:00-14:00	EXPERIENCE WITH TAFAMIDIS IN HEREDITARY TTR AMYLOIDOSIS IN A NON-ENDEMIC AREA OF SPAIN	Galan, Lucia	Madrid, Spain
PC048	Day 3	13:00-14:00	Skin Denervation as an Early Biomarkers of Transthyretin Amyloid Polyneuropathy	Chao, Chi-Chao	Taipei, Taiwan
PC049	Day 3	13:00-14:00	Senile Amyloidosis in the Young – Rare but There	Brouwers, Sofie	Zurich, Switzerland
PC050	Day 3	13:00-14:00	Thermal Quantitative Sensory Testing with the Methods-of-Limits; reference values for early non-invasive detection of debuting TTR amyloidosis neuropathy	Nordh, Erik	Umea, Sweden
PC051	Day 3	13:00-14:00	SURGICAL TECHNIQUES AND OUTCOMES OF DOMINO LIVING DONOR LIVER TRANSPLANTATION	Hayashida, Shintaro	Kumamoto, Japan
PC052	Day 3	13:00-14:00	Correlations among proinflammatory cytokine levels in the aqueous humor of secondary glaucoma patients with familial amyloidotic polyneuropathy	Tsutsumi, Utako	Kumamoto, Japan
PC053	Day 3	13:00-14:00	Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (ATTRm) amyloidosis: Phase 3 APOLLO study subanalysis of Japanese patients	Yamashita, Taro	Kumamoto, Japan
PC054	Day 3	13:00-14:00	Time-dependent changes in bleb parameters of two secondary glaucoma cases with familial amyloidotic polyneuropathy	Nakashima, Kei-Ichi	Kumamoto, Japan
PC055	Day 3	13:00-14:00	Study of Transthyretin-related Amyloidoses at Molecular Level	Yo-Tsen Liu	Taipei, Taiwan
PC056	Day 3	13:00-14:00	Complex situations in spouses of patients with hereditary ATTR amyloidosis	Kukinaka, Chieko	Kumamoto, Japan
PC057	Day 3	13:00-14:00	The role of Stem Cell Transplantation in Patients with Cardiac AL Amyloidosis	Lim, Sung Won	Seoul, Korea
PC058	Day 3	13:00-14:00	Usefulness of Longitudinal Left Atrial Dysfunction Assessed by 2D-strain Echocardiography for Thromboembolic Events Evaluation in Cardiac Amyloidosis	Bodez, Diane	Créteil, France
PC059	Day 3	13:00-14:00	Prognosis of patients with cardiac amyloidosis referred in the French National Referral Center for Cardiac Amyloidosis	Bodez, Diane	Creteil, France
PC060	Day 3	13:00-14:00	The First Case of Wild-Type Cystatin C Amyloidosis Identified from Granulomatous Amyloidoma in the Rectum	Yoshinaga, Tsuneaki	Matsumoto, Japan
PC061	Day 3	13:00-14:00	Elastolysis in hereditary AGel amyloidosis	Koskelainen, Susanna	Espoo, Finland
PC062	Day 3	13:00-14:00	Amyloid-Specific Extraction from FFPE Sections Using Organic Solvents	Kamiie, Junichi	Sagamihara, Japan
PC063	Day 3	13:00-14:00	ALECT2 and NASH	Benson, Merrill	Indianapolis, United States
PC064	Day 3	13:00-14:00	Short-term complications after renal transplantation in AFib E526V (p.Glu545Val) amyloidosis	Costa, Paulo P.	Porto, Portugal

PC065	Day 3	13:00-14:00	Relation Between Myocardial Amyloid Burden by 18F-florbetapir PET and Severity of Heart Failure in Light Chain Amyloidosis	El-Sady, Mohamed Samir	Boston, United States
PC066	Day 3	13:00-14:00	Treatment with pomalidomide and dexamethasone in patients with light chain AL amyloidosis and multiple myeloma	Basset, Marco	Pavia, Italy
PC067	Day 3	13:00-14:00	Systemic heavy and light chain amyloidosis presenting nephrotic syndrome and congestive heart failure: A case presentation and literature review	Otaka, Yukihiro	Takasaki, Japan
PC068	Day 3	13:00-14:00	Renal transplantation in AL amyloid patients - A single center 30 years experience	Angel-Korman, Avital	Boston, United States
PC069	Day 3	13:00-14:00	Linking Immunoglobulin Light Chain Structure, Organ Tropism, and End-Stage Renal Disease in AL Amyloidosis	Prokaeva, Tatiana	Boston, United States
PC070	Day 3	13:00-14:00	Epidemiology of AL amyloidosis in US commercially insured population	Quock, Tiffany P.	South San Francisco, United States
PC071	Day 3	13:00-14:00	Soluble suppression of tumorigenicity 2 (sST2) and growth differentiation factor 15 (GDF-15) help to identify patients with light-chain amyloidosis in the cardiology department	Szczygieł, Justyna A.	Warswa, Poland
PC072	Day 3	13:00-14:00	Light chain amyloidosis: Renal staging system and renal response criteria evaluation. The Mayo cohort.	Drosou, Maria Eleni	Rochester, United States
PC073	Day 3	13:00-14:00	Can we pick a winner in immunoglobulin light chain amyloidosis staging systems?	Muhctar, Eli	Rochester, United States
PC074	Day 3	13:00-14:00	Diagnostic value of liver stiffness as marker of hepatic amyloid deposition in systemic AL amyloidosis	Nienhuis, Hans L.	Groningen, Netherlands
PC075	Day 3	13:00-14:00	Prognostic value of plasma cell disease burden in patients with systemic AL Amyloidosis	Veelken, Kaya	Heidelberg, Germany
PC076	Day 3	13:00-14:00	Molecular features of cell alterations caused by amyloidogenic cardiotropic light chains	Lavatelli, Francesca	Pavia, Italy
PC077	Day 3	13:00-14:00	A Prospective Phase II of Daratumumab in Previously-Treated Systemic LightChain (AL) Amyloidosis	Jaccard, Arnaud	Limoges, France
PC078	Day 3	13:00-14:00	A mouse model to study the toxicity of amyloidogenic light chains	Nuvolone, Mario	Pavia, Italy
PC079	Day 3	13:00-14:00	Asymptomatic heart involvement in AL amyloidosis	Palladini, Giovanni	Pavia, Italy
PC080	Day 3	13:00-14:00	Aortic viscoelastic properties in patients with cardiac amyloidosis	Lucia Salvi	Milan, Italy
PC081	Day 3	13:00-14:00	“WATCH AND WAIT” STRATEGY IN ASYMPTOMATIC (“SMOLDERING”?) AL AMYLOIDOSIS”	Riva, Marcello	Padova, Italy
PC082	Day 3	13:00-14:00	GAIM Fusions Are Therapeutic Candidates for Peripheral Amyloidosis	Fisher, Richard	Cambridge, United States
PC083	Day 3	13:00-14:00	Updated Analysis of Phase 2 Study of Bendamustine and Dexamethasone in Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis	Lentzsch, Suzanne	New York, United States
PC084	Day 3	13:00-14:00	Quality of hematologic response but not depth of NT-proBNP response improves survival of patients with AL amyloidosis who achieve cardiac response	Milani, Paolo	Pavia, Italy

PC085	Day 3	13:00-14:00	Outcome of elderly patients with light chain AL amyloidosis	Milani, Paolo	Pavia, Italy
PC086	Day 3	13:00-14:00	Myocardial Stiffness Measured by a New Noninvasive Method Predicts Adverse Cardiac Events in Patients with Amyloidosis	Pislaru, Cristina	Rochester, United States
PC087	Day 3	13:00-14:00	Prospective Evaluation of Small and Large Fiber Neuropathy in Patients with AL Amyloidosis	Kastritis, Efstathios	Athens, Greece
PC088	Day 3	13:00-14:00	Daratumumab – A Safe First-Line Treatment of Cardiac AL Amyloidosis in Heavily Compromised Patients	Taghizadeh, Hossein	Vienna, Austria
PC089	Day 3	13:00-14:00	Immuno-enrichment Coupled to MALDI-TOF MS Detection Method for Serum Free Light Chains (MASS-FIX+FL)	Murray, David	Rochester, United States
PC090	Day 3	13:00-14:00	Clinical utility of 10-color multiparameter flow cytometric plasma cell immunophenotyping in AL amyloidosis.	Dogan, Ahmet	New York, United States
PC091	Day 3	13:00-14:00	High Sensitivity M-protein Detection in a Case of Cardiac Amyloidosis	Murray, David	Rochester, United States
PC092	Day 3	13:00-14:00	Primary Systemic Amyloidosis in Waldenström Macroglobulinemia	Zanwar, Saurabh	Rochester, United States
PC093	Day 3	13:00-14:00	Cardiac predictors of AL-amyloidosis progression in accordance with renal function	Rameeva, Anna S.	Moscow, Russia
PC094	Day 3	13:00-14:00	Systemic Primary Amyloid Light-chain (AL) amyloidosis with the occurrence of IgD-λ type monoclonal gammopathy of undetermined significance (MGUS)	Itagaki, Mitsuhiro	Hiroshima, Japan
PC095	Day 3	13:00-14:00	NEOD001 binds a wide repertoire of light chain sequences and aggregation states found in AL amyloidosis	Dolan, Philip	South San Francisco, United States
PC096	Day 3	13:00-14:00	Fibrinogen Aa-chain (AFib) renal amyloidosis: Is liver transplant alone sufficient? A case report	Drosou, Maria Eleni	Rochester, United States
PC097	Day 3	13:00-14:00	Obesity-induced AA amyloidosis: case report of a 'diagnosis per exclusionem'	Brunger, Anne Floor	Groningen, Netherlands
PC098	Day 3	13:00-14:00	Amyloidogenic properties of serum amyloid-A and its inhibition as a therapeutic strategy for systemic amyloidosis	Haj, Esraa	Ramat Aviv, Tel Aviv, Israel
PC099	Day 3	13:00-14:00	Tracking amyloid deposits in vivo: Development and regression of multi-organ involvement in a rare case of secondary AA amyloidosis	Ihne, Sandra	Wuerzburg, Germany
PC100	Day 3	13:00-14:00	Engraftment Syndrome Following High Dose Therapy and Autologous Hematopoietic Cell Transplantation in patients with Light Chain (AL) Amyloidosis	Bhatt, Valkal	New York, United States
PC101	Day 3	13:00-14:00	Cardiac involvment in AA amyloidosis: a prospective study on 34 patients	Georgin-Lavialle, Sophie	Créteil, France
PC102	Day 3	13:00-14:00	Ocular AA Amyloid Through Local SAA Induction in Ciliary Body Epithelial Cells in Horses with Ocular Leptospira Infection	Linke, Reinhold	Munich, Germany
PC103	Day 3	13:00-14:00	Production and biochemical analysis of mutated fibrinogen Aα produced by CHO cells with Δ523 AGTC in FGA 'Japan original mutation'	Yoshinaga, Tsuneaki	Matsumoto, Japan
PC104	Day 3	13:00-14:00	Cardiac amyloid in hereditary AGel amyloidosis	Schmidt, Eeva-Kaisa	Espoo, Finland

PC105	Day 3	13:00-14:00	Evaluation of affinity of newly developed radiolabeled compound EISB on normal mice and amyloid deposition mice and its SPECT/CT imaging with 125I-EISB	Tokunaga, Yume	Kumamoto, Japan
PC106	Day 3	13:00-14:00	MALDI Imaging Mass Spectrometry for the study of cardiovascular pathology	Nirasawa, Takashi	Yokohama, Japan
PC107	Day 3	13:00-14:00	Haplotype analysis of newly diagnosed Portuguese and Brazilian families with fibrinogen amyloidosis caused by the FGA p.Glu545Val variant	Lobato, Luísa	Porto, Portugal
PC108	Day 3	13:00-14:00	Clinical, immunohistological and molecular aspects of myocardial amyloidosis – single institution experience	Bacovsky, Jaroslav	Olomouc, Czech
PC109	Day 3	13:00-14:00	Diagnosis of amyloidosis from subcutaneous fat tissue aspirates – morphological examination and proteomic analysis	Bacovsky, Jaroslav	Olomouc, Czech
PC110	Day 3	13:00-14:00	Chronotropic incompetence and autonomic dysfunction as mechanisms of dyspnea in patients with late stage cardiac amyloidosis.	Nativi-Nicolau, Jose	Salt Lake City, United States
PC111	Day 3	13:00-14:00	Pathophysiology of synaptic alpha-synuclein in Parkinson's disease	Bergstrom, Joakim	Uppsala, Sweden
PC112	Day 3	13:00-14:00	Clinical Characteristics of Patients with Positive and Negative 99mTc-labeled Pyrophosphate scintigraphy	Kyohei, Marume	Kumamoto, Japan
PC113	Day 3	13:00-14:00	Mode of Death in Cardiac Amyloidosis	Kharoubi, Mounira	Créteil, France
PC114	Day 3	13:00-14:00	A multidisciplinary and interprofessional therapeutic education program for patients suffering from amyloidosis: Amylo-PEP (Amyloidosis patient education program)	Pompougnac, Julie	Créteil, France
PC115	Day 3	13:00-14:00	Prevalence, determinant and consesequences of Interatrial Asynchronism in Cardiac Amyloidosis	Thibaud Damy	Paris, France
PC116	Day 3	13:00-14:00	Intraislet Spreading of IAPP-amyloid	Westermark, Gunilla	Uppsala, Sweden
PC117	Day 3	13:00-14:00	Advanced glycation end products in systemic amyloidosis	Nienhuis, Hans L.	Groningen, Netherlands
PC118	Day 3	13:00-14:00	Classification of Amyloidosis. Comparison of Immunohistochemistry Using Fibril-specific Antibodies and Mass Spectrometry in a Blinded Fashion	Linke, Reinhold	Munich, Germany
PC119	Day 3	13:00-14:00	Unravelling the Unexplored Amyloidogenicity of the αCGRP hormone	Tsiolaki, Paraskevi	Athens, Greece
PC120	Day 3	13:00-14:00	The Amyloid Interactome: Mapping Protein Aggregation	Nastou, Aikaterini-Despoina	Athens, Greece